Logo image
Back
Clinical Outcomes in Peripheral Ulcerative Keratitis
Journal article   Peer reviewed

Clinical Outcomes in Peripheral Ulcerative Keratitis

Krishna Mallem, Paulina Liberman, Meghan K. Berkenstock, James T. Walsh, Bryn M. Burkholder, Douglas A. Jabs and Jennifer E. Thorne
American journal of ophthalmology, v 272, pp 98-105
01 Apr 2025
DOI: https://doi.org/10.1016/j.ajo.2025.01.014
PMID: 39870340
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Life Sciences & Biomedicine Science & Technology Ophthalmology
center dot PURPOSE: To evaluate clinical and treatment outcomes in patients with peripheral ulcerative keratitis (PUK). center dot DESIGN: Retrospective, case series center dot SUBJECTS: Patients diagnosed with PUK at the Wilmer Eye Institute between January 2003 and October 2022. center dot METHODS: Data collected included demographics, presence of systemic disease, disease laterality, duration of disease, PUK activity, presence of corneal perforation, and treatments. Outcomes of interest included: disease control, corticosteroid-sparing success, corticosteroiddiscontinuation success, sustained drug-free remission, disease reactivation, occurrence of perforation, and need for surgery. center dot RESULTS: Fifty-seven patients with PUK were identified. The median age was 53 years, with 46% of patients being Black. Most patients (56%) had an associated systemic diagnosis. The median duration of symptoms prior to presentation was 3 months and 42% of patients presented with bilateral disease. Of the 81 affected eyes, 7 had perforated prior to presentation. During a median follow-up of 3 years, 76% of patients received oral prednisone and 80% received at least 1 immunosuppressive drug. Disease control was achieved in all patients within a median of 1.3 months. The rates of corticosteroid-sparing success and corticosteroid discontinuation were 0.44 per patient-year (/PY) and 0.27/PY, respectively. Sustained drug-free remission was achieved in only 6% of patients. During follow-up, the rate of corneal perforation was 0.009/EY. The rate of disease reactivation was 0.07/EY, with a median time to reactivation of '-2 years. center dot CONCLUSIONS: Over a moderate amount of follow-up, systemic therapy achieved disease control, corticosteroidsparing and corticosteroid discontinuation. However, sustained drug-free remission was infrequent in our cohort.

Metrics

1 Record Views
4 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Ophthalmology
Logo image